Form 4: Ionis Pharmaceuticals Director B. Lynne Parshall Reports Stock Option and Restricted Stock Unit Grants

Director B. Lynne Parshall reports receiving stock options and restricted stock units from Ionis Pharmaceuticals as part of their non-employee director compensation.

Summary

• On July 1, 2024, B. Lynne Parshall, a director of Ionis Pharmaceuticals, received stock options for 10,111 shares and 4,079 restricted stock units (RSUs).
• The stock options have an exercise price of $47.11 and vest on the earlier of July 1, 2025, or the next annual meeting, expiring on June 30, 2034.
• The RSUs also vest on the earlier of July 1, 2025, or the next annual meeting, and will be delivered on July 15 following the vesting date.
• These grants were adjusted to ensure the director's annual equity compensation does not exceed $450,000, based on the grant date fair value.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock options and RSUs to a director, indicating standard corporate governance practices. It's a neutral event with a slightly positive sentiment due to aligning director interests with shareholders.

Positives

• The grants align the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

Stock option and RSU grants are common forms of compensation for directors of publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Director compensation packages vary widely across the pharmaceutical industry, but equity-based compensation is a standard component.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and RSUs in their director compensation plans.
• The $450,000 cap on annual equity compensation appears to be within a reasonable range for non-executive directors in comparable companies.

Stakeholder Impact

• The grants align the director's interests with those of the shareholders, potentially leading to better decision-making.
• The grants have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates